№ lp_2_3_61126
File format: docx
Character count: 41267
File size: 350 KB
This document presents a comprehensive molecular classification for adenocarcinomas of the gastroesophageal junction, distinguishing them from esophageal and gastric adenocarcinomas, based on gene sequencing and tumor classification methods.
Year:
2016
Region / city:
Seoul, Korea
Subject:
Medical research, Oncology
Document type:
Supplementary Methods
Organization / institution:
Seoul National University, Jackson Laboratory for Genomic Medicine, MD Anderson Cancer Center
Authors:
Yun-Suhk Suh, Deukchae Na, Ju-Seog Lee, Jeesoo Chae, EuiHyun Kim, Giyong Jang, Jieun Lee, Jimin Min, Chan-Young Ock, Seong-Ho Kong, Joshy George, Chengsheng Zhang, Hyuk-Joon Lee, Jong-Il Kim, Seong-Jin Kim, Woo Ho Kim, Charles Lee, Han-Kwang Yang
Target audience:
Researchers, medical professionals, academicians
Date of approval:
2016
Date of modifications:
None
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2026
Dataset:
IRCC gastroesophageal adenocarcinomas
Gene:
EGFR
Number of tumors analyzed:
44
Type of data:
Supplementary table
Method:
qReal Time PCR
Sample type:
Patient tumors and corresponding PDX when available
Notes:
Tumors with heterogeneous copy number gain marked with a star
Version:
GastricHER2Biomarkers 1.0.0.1
Protocol Posting Date:
June 2017
Year:
2017
Region / city:
United States
Topic:
HER2 biomarker testing, gastric cancer, gastroesophageal junction
Document type:
Guideline
Organization / institution:
College of American Pathologists, American Society for Clinical Pathology, American Society of Clinical Oncology
Author:
Angela N. Bartley, MD; Jessi Christ, CTR; Patrick Fitzgibbons, MD; Stanley R. Hamilton, MD; Sanjay Kakar, MD; Manish A. Shah, MD; Laura H. Tang, MD, PhD; Megan L. Troxell MD, PhD
Target audience:
Pathologists, oncologists, clinical laboratories
Period of validity:
Indefinite
Date of approval:
June 2017
Date of changes:
N/A
Year:
2026
Dataset:
IRCC gastroesophageal adenocarcinomas
Gene:
EGFR
Number of tumors analyzed:
44
Type of data:
Supplementary table
Method:
qReal Time PCR
Sample type:
Patient tumors and corresponding PDX when available
Notes:
Tumors with heterogeneous copy number gain marked with a star
Year:
2023
Study Type:
Clinical trial, Phase 2
Document Type:
Supplementary data
Authors:
Samuel J. Klempner et al.
Intervention:
Zolbetuximab monotherapy, Zolbetuximab + mFOLFOX6, Zolbetuximab + Pembrolizumab
Population:
Patients with advanced or metastatic claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma
Sample Size:
54
Countries:
France, Italy, Japan, Korea, Taiwan, United States
Cohorts:
1A, 2, 3A
Age Range:
32–79 years
Median Age:
60–65 years
Sex Distribution:
Male 33, Female 21
Ethnicity:
Asian 43%, White 43%, Black 2%, Hispanic/Latino 6%
PK Sampling:
Zolbetuximab, mFOLFOX, Pembrolizumab
HRQOL Assessment:
Multiple cycles per cohort
Follow-up:
30-day safety, 90-day follow-up
Geographic Focus:
Eastern Asia, Central/Eastern Europe, United States, France
End Points:
Pharmacokinetics, health-related quality of life, patient demographics
Data Sources:
Clinical study data, GLOBOCAN 2020, literature references
Supplementary Materials:
Methods, Tables, Figures
Year:
2026
Region / City:
Kainuu, Finland
Document Type:
Medical appointment instructions
Institution:
Kainuu Central Hospital
Target Audience:
Pediatric patients and their guardians
Preparation Requirements:
Fasting 2 hours before examination, bring drink in bottle or breast-feed
Examination Duration:
10 minutes
Examination Focus:
Lower esophagus and upper stomach to monitor reflux
Post-Examination Instructions:
No special treatment required, results communicated by attending physician
Contact Information:
Telephone provided for rescheduling or inquiries
Fees:
Possible charge for missed or non-cancelled appointments
Year:
2025
Region / City:
Maisons-Alfort, France
Subject:
Esophageal pathologies, pediatric surgery, biotherapy, genetics, minimally invasive surgery
Document Type:
Prize announcement and application guidelines
Organization:
Association Française de l’Atresie de l’Oesophage (AFAO)
Chairperson:
Viviane Armand
Deadline for Applications:
May 21, 2025
Announcement Date:
June 25, 2025
Presentation Date:
June 28, 2025
Funding Amount:
approximately €15,000 (depending on fundraising)
Eligibility:
Clinical and preclinical research projects on esophageal diseases
Evaluation Criteria:
Originality, feasibility, scientific quality, patient relevance
Required Compliance:
Regulatory authorizations for clinical studies, animal research regulations
Year:
2023
Region / City:
Not specified
Topic:
Thoracic esophagectomy, survival outcomes, esophageal cancer
Document Type:
Research article
Institution:
Not specified
Author:
Not specified
Target Audience:
Medical professionals, researchers in oncology
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2026
Region:
Not specified
Research Field:
Oncology
Document Type:
Clinical study report
Institution:
Not specified
Author:
Not specified
Target Population:
ESCC patients
Study Period:
Not specified
Data Analysis Methods:
Univariate and multivariate Cox regression, Kaplan–Meier survival curves, Chi-square test
Variables Analyzed:
Age, sex, tumor location, grade, T stage, stage, primary tumor length, tumor types, lymphatic invasion, perineural invasion, lymphangio vascular invasion, postoperative chemotherapy
Survival Outcomes:
Overall survival, stratified survival by stage, lymph node status, T stage, and chemotherapy
Statistical Significance Threshold:
p < 0.05
Sample Size:
195 patients
Follow-up:
Postoperative
Year:
2023
Region / City:
Not specified
Topic:
Health-related quality of life after esophageal cancer treatment
Document Type:
Research Article
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Researchers, healthcare professionals, medical practitioners
Period of Application:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
Not specified
Region / Location:
Hypothetical / United States context implied
Topic:
Epidemiology, Nutritional and Environmental Risk Factors, Cancer Research
Document Type:
Educational Practice Problems
Institution / Organization:
Not specified
Author:
Not specified
Target Audience:
Students or trainees in epidemiology or public health
Study Designs Covered:
Cross-sectional, Prospective Cohort, Case-Control
Variables Analyzed:
Obesity status, Vegetable intake, Pesticide exposure, Alcohol consumption, Asthma, Esophageal cancer
Time Frame:
10-year follow-up for cohort study
Statistical Measures:
Measures of association, Odds ratio, p-value
Data Collection Method:
Self-report, Interviews
Limitations:
Potential biases and study design weaknesses discussed
Year:
2026
Region / City:
Not specified
Subject:
Oncology, Immunology
Document type:
Supplementary Figure
Institution:
Not specified
Authors:
Not specified
Target audience:
Researchers, Clinicians
Study focus:
CD8 densities and PD-L1 expression in small cell and esophageal carcinomas
Data type:
Quantitative immunohistochemical analysis
Tumor types:
Small cell lung carcinoma, small cell carcinoma of the prostate, small cell carcinoma of the bladder, small cell carcinoma of the esophagus, esophageal squamous cell carcinoma, esophageal adenocarcinoma
Measurement methods:
Immunohistochemistry, Tumor-infiltrating immune cells analysis